Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

Clinical trial NCT07627711 · RECRUITING

Trial details

NCT number: NCT07627711
Sponsor: Beijing Biotech
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Pancreatic Ductal Adenocarcinoma (PDAC)Unresectable Locally Advanced Metastatic Disease

Start date: 2026-03-02
Primary completion: 2027-04-14
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.